1. Volume 23, Issue 3, Pages 591-601 (March 2015)
Synthetic Consensus HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin in HIV Infected Individuals 
Matthew P Morrow, Pablo Tebas, Jian Yan, Lorenzo Ramirez, Anna Slager, Kim Kraynyak, Malissa Diehl, Divya Shah, Amir Khan, Jessica Lee, Jean Boyer, J Joseph Kim, Niranjan Y Sardesai, David B Weiner, Mark L Bagarazzi 
Molecular Therapy 
Volume 23, Issue 3, Pages (March 2015)
DOI: /mt
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

2. Figure 1
Clinical study design. (a) Schematic of eligibility determination, enrollment, and study conduct. (b) Schedule of events for study participants, indicating timing of treatments, assessment of pain, and blood collection for immunologic and virologic assays. D, days; EP, electroporation; VAS, visual analog scale; Wk, week.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

3. Figure 2
Visual analog scale (VAS) scores over time postinjection and electroporation (EP). (a) Pain levels were captured at 0, 5, and 10 minutes after dose/EP on day 0, week 4, week 8, and week 16. (b) Median VAS scores are represented for N = 12 subjects except for the week 4 dose at 5 minutes, which represents N = 11.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

4. Figure 2
Visual analog scale (VAS) scores over time postinjection and electroporation (EP). (a) Pain levels were captured at 0, 5, and 10 minutes after dose/EP on day 0, week 4, week 8, and week 16. (b) Median VAS scores are represented for N = 12 subjects except for the week 4 dose at 5 minutes, which represents N = 11.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

5. Figure 3
PENNVAX-B drives production of interferon-γ (IFNγ). (a) Left panel: ELISpot responses to individual Gag, Pol, and Env antigens included in the PENNVAX-B formulation on day 0, the Peak of response or Memory (8 months following the final dose). Right panel: Cumulative ELISpot responses to all three HIV antigens on day 0, Peak, and Memory. (b) ELISpot responses with responders and nonresponders indicated for the given sample listed. (c) ELISpot responses attributable specifically to PENNVAX-B. *Peak and Memory samples are the same. (d) Per patient ELISpot responses broken out by antigen. (e) ELISpot response rates for all patients.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

6. Figure 4
CD8+ T cells display phenotypic markers of cytotoxic T lymphocytes (CTLs) after treatment with PENNVAX-B. (a) Frequencies of CD8+ T cells expressing perforin, granzyme B, and CD107a shown per subject and by responses to individual antigenic components of PENNVAX-B. (b) Distribution of CD8+ T cells exhibiting a CTL phenotype by distinct memory lineages using expression of CD45RO and CD27.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

7. Figure 5
PENNVAX-B allows for activation, loading of lytic granules, and expression of homing integrins on CD8+ T cells. (a) Representative gating strategy and positive staining for CD137, granzyme B, perforin, and β7 Integrin in response to HIV antigen in CD8+ T-cell subset. (b) Left panel: Frequency of CD8+ T cells expressingCD137 (41BB) activation marker in response to HIV antigen or an irrelevant peptide control on day 0, at Peak immune response and from Memory sample (8 months following the final dose). Right panel: Antigen-specific responses with reactive individuals shown in red and NonReactive shown in blue. (c) Top left panel: Frequency of copositivity for granzyme B and perforin within the CD137+/CD8+ T-cell subset. Top right panel: HIV-specific fold increases in copositivity on day 0 compared with Peak or Memory samples. Bottom left panel: Frequency of CD137+/granzyme B+/perforin+ CD8+ T cells (putative CTLs) upon stimulation with irrelevant antigen or HIV antigen. Bottom right panel: Antigen-specific responses with reactive individuals shown in red and nonreactive shown in blue. (d) Left panel: Frequency of CTLs identified in c that also express mucosal homing Integrin β7. Right panel: Antigen-specific responses with Reactive individuals shown in red and nonreactive s shown in blue. (e) Lytic granule loading reactivity summary for all patients.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

8. Figure 5
PENNVAX-B allows for activation, loading of lytic granules, and expression of homing integrins on CD8+ T cells. (a) Representative gating strategy and positive staining for CD137, granzyme B, perforin, and β7 Integrin in response to HIV antigen in CD8+ T-cell subset. (b) Left panel: Frequency of CD8+ T cells expressingCD137 (41BB) activation marker in response to HIV antigen or an irrelevant peptide control on day 0, at Peak immune response and from Memory sample (8 months following the final dose). Right panel: Antigen-specific responses with reactive individuals shown in red and NonReactive shown in blue. (c) Top left panel: Frequency of copositivity for granzyme B and perforin within the CD137+/CD8+ T-cell subset. Top right panel: HIV-specific fold increases in copositivity on day 0 compared with Peak or Memory samples. Bottom left panel: Frequency of CD137+/granzyme B+/perforin+ CD8+ T cells (putative CTLs) upon stimulation with irrelevant antigen or HIV antigen. Bottom right panel: Antigen-specific responses with reactive individuals shown in red and nonreactive shown in blue. (d) Left panel: Frequency of CTLs identified in c that also express mucosal homing Integrin β7. Right panel: Antigen-specific responses with Reactive individuals shown in red and nonreactive s shown in blue. (e) Lytic granule loading reactivity summary for all patients.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions